Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ijgc-2024-006091 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development.
Cancer Discov
November 2024
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs.
View Article and Find Full Text PDFCancer therapy-related interstitial lung disease.
Chin Med J (Engl)
October 2024
State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
Article Synopsis
- The use of cancer therapies is increasing, leading to more cases of lung injuries, specifically interstitial lung disease (ILD), which is a significant cause of death in patients.
- Cancer therapy-related ILD (CT-ILD) can arise from various treatments like chemotherapy, immunotherapy, and radiotherapy, and can develop quickly and severely, highlighting the need for rapid diagnosis and treatment.
- This review covers the risk factors, mechanisms, clinical features, and diagnostic methods for CT-ILD, along with treatment strategies for grading, typing, and staging the condition.
Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.
Pharmaceutics
September 2024
WIR-Walk In Ruhr, Center for Sexual Health & Medicine, Department of Dermatology, Venerology and Allergology, Ruhr-University Bochum, 44787 Bochum, Germany.
Article Synopsis
- Biological barriers pose significant challenges in the development of new therapies, as drugs must navigate various protective layers at both the tissue and cellular levels to effectively target specific cells.
- A diverse range of therapeutic options is now available, from small molecules to advanced techniques like gene therapies and monoclonal antibodies, with recent innovations rapidly transforming treatment approaches.
- Notable advancements, such as the FDA approval of new RNA-based therapies and viral-vector gene therapies for hemophilia, exemplify the potential for innovative medicines to address complex diseases and improve patient care.
The rise of antibody-drug conjugates in advanced endometrial cancer.
Int J Gynecol Cancer
December 2024
Hospital 9 de Julho, São Paulo, São Paulo, Brazil.
Living in LALA land? Forty years of attenuating Fc effector functions.
Immunol Rev
November 2024
mAbsolve Limited, Oxford, UK.
The Fc region of antibodies is vital for most of their physiological functions, many of which are engaged through binding to a range of Fc receptors. However, these same interactions are not always helpful or wanted when therapeutic antibodies are directed against self-antigens, and can sometimes cause catastrophic adverse reactions. Over the past 40 years, there have been intensive efforts to "silence" unwanted binding to Fc-gamma receptors, resulting in at least 45 different variants which have entered clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!